tbuckley/cabot-search huggingface dataset:
Replacement of Rat Tracheas by Layered, Trachea‐Like, Scaffold‐Free Structures of Human Cells Using a Bio‐3D Printing System
Authors: Ryusuke Machino, Keitaro Matsumoto, Daisuke Taniguchi, Tomoshi Tsuchiya, Yosuke Takeoka, Yasuaki Taura, Masaaki Moriyama, Tomoyuki Tetsuo, Shosaburo Oyama, Katsunori Takagi, Takuro Miyazaki, Go Hatachi, Ryoichiro Doi, Koichiro Shimoyama, Naoto Matsuo, Naoya Yamasaki, Koichi Nakayama, Takeshi Nagayasu
Journal: Advanced Healthcare Materials (2019)

Abstract Current scaffold‐based tissue engineering approaches are subject to several limitations, such as design inflexibility, poor cytocompatibility, toxicity, and post‐transplant degradation. Thus, scaffold‐free tissue‐engineered structures can be a promising solution to overcome the issues associated with classical scaffold‐based materials in clinical transplantation. The present study seeks to optimize the culture conditions and cell combinations used to generate scaffold‐free structures using a Bio‐3D printing system. Human cartilage cells, human fibroblasts, human umbilical vein endothelial cells, and human mesenchymal stem cells from bone marrow are aggregated into spheroids and placed into a Bio‐3D printing system with dedicated needles positioned according to 3D configuration data, to develop scaffold‐free trachea‐like tubes. Culturing the Bio‐3D‐printed structures with proper flow of specific medium in a bioreactor facilitates the rearrangement and self‐organization of cells, improving physical strength and tissue function. The Bio‐3D‐printed tissue forms small‐diameter trachea‐like tubes that are implanted into rats with the support of catheters. It is confirmed that the tubes are viable in vivo and that the tracheal epithelium and capillaries proliferate. This tissue‐engineered, scaffold‐free, tubular structure can represent a significant step toward clinical application of bioengineered organs.
AB0754 Long-term follow-up of 214 primary raynaud’s phenomenon patients
Authors: F.M. Ortiz Sanjuan, C. Alcañiz Escandell, K.R. Arevalo Ruales, I. Chalmeta Verdejo, M. De la Rubia. Navarro, C. Feced Olmos, J.J. Fragio Gil, R. Gonzalez Mazario, L. Gonzalez Puig, E. Labrador Sánchez, I. Martinez Cordellat, R. Negueroles Albuixech, E. Grau Garcia, J. Ivorra Cortés, J.E. Oller Rodriguez, E. Vicens Bernabeu, C. Najera Herranz, I. Canovas Olmos, J.A. Roman Ivorra
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Raynaud's phenomenon (RP) is frequently associated with the presence of scleroderma or other connective tissue diseases (CTD). Identify the presence of secondary RP is important to perform an adequate therapeutic management and to achieve the early control of these patients. Nailfold capillaroscopy is safe, economic, and relatively easy to perform and has proven to be useful in identifying patients with secondary RP. <h3>Objectives</h3> To assess a long-term follow-up primary RP patient's series. <h3>Methods</h3> Retrospective observational study of a wide and unselected series of patients diagnosed as primary RP from a single university hospital from January 2012 to August 2017. Patients were classified as primary RP after the presence of CTD at the onset was excluded. <h3>Results</h3> We studied 214 patients (85.98% were female), with a mean age of 47.6±16.7 years (range 15–88). After a mean follow-up period of 46.4±23.3 months, 8 patients were diagnosed of a CTD (2 Scleroderma/Systemic sclerosis, 3 Systemic Lupus Erythematosus, 1 Rheumatoid arthritis and 2 Sjogren's syndrome). The remaining 206 patients continued classified as primary RP. The main capillaroscopic patterns observed were: Normal (n=157), unspecific (n=49), scleroderma pattern (n=2) and suggestive of other rheumatic diseases pattern (n=6). All patients who developed a CTD during the follow-up, showed changes in successive nailfold capillaroscopic examinations. 20 of 206 patients who remained primary RP showed minor changes at successive nailfold capillaroscopy. The main capillaroscopic changes detected on this group were: presence of capillary tortuosity (n=4), presence of a decreased capillary density<sup>2</sup> and the presence of capillary bleeding (n=16). Antinuclear antibodies (ANA) were positive at the onset in 34 patients and after follow-up in 39 patients. <h3>Conclusions</h3> After a mean follow-up period next to four years, most of our primary RP patients remained free of CTD. A minority of our patients showed changes at nailfold capillaroscopy exam or positivity of ANA. <h3>Disclosure of Interest</h3> None declared
SAT0306 Finger flexor tendon pulley complex involvement in psa dactylitis: an ultrasonography study
Authors: I. Tinazzi, D. Mc Gonagle, A. Zabotti, P. Macchioni, S.Z. Aydin
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Dactylitis is a hallmark of psoriatic arthritis (PsA) occurring in around 40% of cases at some point in the disease course. At the micro anatomical level PsA is strongly linked to disease localisation to entheses and other sites of high mechanical stress. Recently high resolution MRI has shown prominent abnormalities at the mini-entheses of the flexor tendon pulleys may be common <h3>Objectives</h3> . In this study we aimed to understand the changes within the pulleys for patients with PsA, with or without dactylitis to explore the role of the pulley disease in the dactylitis. <h3>Methods</h3> Consecutive 20 cases of PsA with dactylitis were recruited and had an US scan of the A1, A2 and A4 pulleys of the digit with dactylitis and the contralateral side. A high resolution probe (22 MHZ) was used to explore a) the thickness of the pulleys, b) the presence of Doppler signals. A comparison was made within digits with or without dactylitis <h3>Results</h3> Half of the A1 pulleys with dactylitic digits had Doppler signals (10/20, 50%), which was less common in A2 (6/20 (30%)) and A4 pulleys (6/20 (30%)) (figure). The digits without dactylitis had Doppler signals less frequently (A1: 1/19 (5%); A2: 1/19 (5%) A4: 1/19 (5%)) A1, A2 and A4 pulleys were significantly thicker in dactylitis fingers compared to fingers without dactylitis, both in longitudinal and transverse planes (table 1). <h3>Conclusions</h3> This study demonstrates that pulleys contribute to the pathogenesis of dactylitis with increased vascularity and thickening, probably due to the micro-enthesitis at the level where the flexor tendons are exposed to high mechanical stress. This is important to understand the anatomical basis of a complex disease feature in PsA, dactylitis <h3>Disclosure of Interest</h3> None declared
Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia
Authors: Adrien Contejean, Matthieu Resche-Rigon, Jérôme Tamburini, Marion Alcantara, Fabrice Jardin, Etienne Lengline, Lionel Ades, Didier Bouscary, Ambroise Marçais, Delphine Lebon, Cécile Moluçon-Chabrot, Louis Terriou, Fiorenza Barraco, Anne Banos, Lucile Bussot, Jean-Yves Cahn, Pierre Hirsch, Natacha Maillard, Laurence Simon, Luc Mathieu Fornecker, Gerard Socie, Regis Peffault De Latour, Flore Sicre De Fontbrune
Journal: Blood (2018)
OP0127 Can achieving minimal disease activity (MDA) prevent progression of subclinical atherosclerosis and arterial stiffness? a two-year prospective cohort study in psoriatic arthritis
Authors: T.H. Cheng, Q. Shang, E. K. M. Li, P.C.H. Wong, L.H.P. Tam, T.Y. Zhu, M.M. Chang, J.J.W. Lee, C.K. Wong, A.P.W. Lee, L.S. Tam
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> PsA patients have higher CVD risk due to underlying inflammation.While achieving MDA was associated with articular benefits, its effect on CVD risk remained uncertain <h3>Objectives</h3> To investigate effect of achieving MDA on subclinical atherosclerosis and arterial stiffness <h3>Methods</h3> Subjects without CVD were recruited and received protocolised treatment aiming at MDA for 2 years. High-resolution ultrasound(for subclinical atherosclerosis) and arterial stiffness were assessed yearly. The primary objective was to investigate the effect of achieving MDA(MDA group)at 12 months on the progression of subclinical atherosclerosis(carotid intima-media thickness[IMT] and plaque)over 2 years. Secondary objectives were to compare1)changes in arterial stiffness(branchial-ankle pulse wave velocity[PWV] and augmentation index[AIX])over 2 years between MDA and non-MDA group;2)changes in vascular outcomes in patients who could or could not achieved sustained MDA(sMDA,defined as achievingMDA from month12 to24).Carotid plaque progression was defined as an increase in number/region harbouring plaque compared with baseline <h3>Results</h3> 90 patients [male:52(58%); age: 50±11] were included. At 24 months, 62 (69%)were on csDMARDs, 20 (22%)were on anti-TNF-α and 8 (9%)were on Secukinumab. Proportion of patient achieved MDA increased significantly(baseline:17%;12 months:64%;24 months:69%) after intensive treatment. Vascular outcomes were similar between MDA and non-MDA group (figure 1).41 (46%)patients achieved sMDA. At baseline, a higher prevalence of subjects in the non-sMDA group were smokers, treated with NSAIDS and csDMARDs;fewer subjects were on bDMARDs, and they had higher disease activity compared with the sMDA group. 34 (38%)of them had plaque progression and prevalence was numerically higher in the non-sMDA group[22 (45%)vs 12 (29%), p=0.13]. Using multivariate analysis, achieving sMDA had protective effect on plaque progression[OR=0.27, 95% CI: 0.09 to 0.84, p=0.03]after adjustment of baseline difference(table 1). Achieving sMDA was also related to less progression of total plaque area(TPA),mean and maxIMT,PWV and AIX(table 1) <h3>Conclusions</h3> Effective suppression of inflammation by achieving sustained MDA may prevent subclinical atherosclerosis and arterial stiffness progression in PsA patients <h3>Acknowledgements</h3> Health and Medical Research Fund for funding support <h3>Disclosure of Interest</h3> None declared
Archived Bone Marrow Smears Are an Excellent Source for NGS-Based Mutation Detection in Acute Myeloid Leukemia
Authors: Adil S.A. Al Hinai, Francois G. Kavelaars, Melissa Rijken, Tim Grob, Kirsten Gussinklo, Annelieke Zeilemaker, Claudia Erpelinck-Verschueren, Mathijs A. Sanders, Kirsten van Lom, Peter J.M. Valk
Journal: Blood (2018)
Clinical implications of increased testing in primary care
Authors: Jessica Watson, Fergus Hamilton, Sarah Bailey, Luke Mounce, Willie Hamilton
Journal: BMJ (2019)

O’Sullivan and colleagues showed a marked increase in test usage in primary care.1 This has implications not only for general practitioner workload, but also for clinicians interpreting test results. Despite rising testing rates we are not seeing a concomitant rise in disease incidence. Presumably testing is shifting …
AB0715 Giant cell arteritis is comorbid with tuberculosis
Authors: Y. Zhang, D. Wang, Y. Yin, X. Zeng
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Giant cell arteritis (GCA) is a medium- and large-vessel vasculitis with an onset age after 50 years, whereas Takayasu arteritis (TA) is a rare large-vessel vasculitis with an onset age younger than 40 years. The association between TA and tuberculosis (TB) was suggested. However, the association between GCA and TB was rarely reported. <h3>Objectives</h3> To understand the association between TA and TB <h3>Methods</h3> Clinical data between November 1998 and October 2017 at PUMCH, Beijing, China, were retrospectively reviewed. Ninety-one patients diagnosed with GCA were included in the study. Precise clinical data were collected and analysed. <h3>Results</h3> A total of 20 patients (22.0%) had a history of active tuberculosis and received anti-tuberculosis therapy. On comparing the clinical features of the patients with TB and those without TB, obvious weight loss (p<i>=</i>0.011), lower percentage of dyslipidemia (p<i>=</i>0.042), higher percentage of anti-phospholipid (p<i>=</i>0.010), and lower white blood cells (p<i>=</i>0.006) were noted in the TB group. <h3>Conclusions</h3> This study demonstrated that the percentage of TB history in patients with GCA was higher than that in the general population. The definite association between TB and GCA remains unknown. Hence, further studies are required to elucidate the mechanisms underlying TB in the pathogenesis of GCA. Clinicians should recognise the possibility of comorbid TB in patients with obvious weight loss and relatively lower white blood cell count. <h3>References</h3> [1] Smith JH, Swanson JW. Giant cell arteritis. Headache2014;54(8):1273–89. [2] van Timmeren MM, Heeringa P, Kallenberg CG. Infectious triggers for vasculitis. Curr Opin Rheumatol2014;26(4):416–23. [3] Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum1990;33(8):1122–8. [4] Walters HM, Aguiar CL, Macdermott EJ, et al. Takayasu arteritis presenting in the context of active tuberculosis: a pediatric case. J Clin Rheumatol2013;19(6):344–7. [5] Carvalho ES, de Souza AW, Leao SC, et al. Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clin Rheumatol2017;36(1):205–8. [6] Alba MA, Mena-Madrazo JA, Flores-Suarez LF. Giant cell arteritis and disseminated tuberculosis: presentation of two cases. Scand J Rheumatol2013;42(6):509–12. <h3>Acknowledgements</h3> We thank all the physicians from department of internal medicine of PUMCH participated in the caring of this patients. <h3>Disclosure of Interest</h3> Y. Zhang Grant/research support from: Chinese Research Special Fund for Public Welfare Industry of Health (grant number 201502024) , D. Wang: None declared, Y. Yin: None declared, X. Zeng: None declared
FRI0705-HPR Comparison of pain behavior of individuals with different rheumatic disease
Authors: E. Ünal, G. Arın, N.B. Karaca, S. Öksüz, F.B. Oflaz, A. Özçadırcı, Y. Yakut, S. Apraş Bilgen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Pain is an important symptom in rheumatic diseases. Chronic pain is strongly associated with cognition, anxiety and depression levels in these patients.<sup>1 2</sup> Pain behavior can be related to the patient9s response to the disease and the use of painkillers. <h3>Objectives:</h3> The aim of this study is to compare the pain behavior of patients with different rheumatic diseases. <h3>Methods:</h3> Patients with Ankylosing Spondylitis (AS), Fibromyalgia (FM), and Rheumatoid Arthritis (RA) were included in the study and their demographic data were recorded. The Hospital Anxiety and Depression Scale (HADS) was used to determine the anxiety and depression levels of patients. Health Assessment Questionnaire (HAQ) was used to determine functional status and Cognitive Exercise Therapy Approach Scale (the authors request that the abbreviation stays as "BETY" as the original in Turkish) was used to assess bio-psychosocial status of the patients.<sup>3</sup> The first and fourth questions of BETY were used to investigate pain behavior. <h3>Results:</h3> The mean age of 329 patients were 45,5±11,5 years and the body mass index was 27,8±5,9. The patient's HAQ score was 12,5±10,5, the HADS anxiety score was 8,7±5,2 and the HADS depression score was 7,50±4,6. The BETY total score was 62.6±26.3. According to BETY scale's 1st question, although the patients felt pain, the rate of continuing activity was 42.6% and the non-continuity rate was 13.4%. According to BETY scale's 4th question, the painkiller using rate was 27.8% and the non-painkiller rate was 25.3% (table 1). <h3>Conclusions:</h3> Although patients knew that their pain would increase, it was determined that the patients had continued their activities. It was also found that the use of painkillers was higher in AS patients compared to the others. It was concluded that these groups should be trained in regarding to restricting their activities when they felt pain. <h3>References</h3> 1. Shim EJ, Hahm BJ, Go DJ, Lee KM, Noh HL, Park SH, et al. Modeling quality of life in patients with rheumatic diseases: the role of pain catastrophizing, fear-avoidance beliefs, physical disability, and depression. Disability and rehabilitation2017:1–8. 2. Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nature reviews Rheumatology2011;7(4):216–24. 3. Ünal E, Arin G, Karaca Nb, Kiraz S, Akdoğan A, Kalyoncu U, et al. Romatizmalı hastalar için bir yaşam kalitesi ölçeğinin geliştirilmesi: madde havuzunun oluşturulması. Journal of Exercise Therapy and Rehabilitation2017;4(2):67–75. <h3>Disclosure of Interest:</h3> None declared
THU0114 Influence of autoantibody status in time to initiate dmards in patients with early rheumatoid artrhitis
Authors: J. Molina Collada, M.G. González Álvarez, V. Navarro-Compán, L. Nuño Nuño, D. Peiteado, A. Villalba, P. Bogas, A. Balsa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Factors contributing to an early referral to Rheumatologist and DMARDs initiation following symptom onset in rheumatoid arthritis (RA) patients are unclear. Recent data suggest that ACPA/RF double seropositivity is associated with delayed presentation to primary care and DMARDs initiation. Identification of these factors is mandatory to faciliate an early diagnosis and treatment of RA patients. <h3>Objectives</h3> To determine whether time to DMARDs initiation and time to first visit at early arthritis clinic (EAC) following symptoms onset differs between RA patients according to autoantibody status. <h3>Methods</h3> A prospective analysis of an EAC cohort including 1377 referred patients from 1993 to 2017 was undertaken for this study. Patients diagnosed of RA (according to physician's diagnosis) were selected. Based on the serological status, we clasified patients in 4 groups: RF+/ACPA+, RF-/ACPA+, RF+/ACPA-, RF-/ACPA-. A baseline clinical assessment was completed including time (months) from symptoms onset to first assessment at EAC and to DMARD initiation. First, differences between serotypes were tested using chi-squared and student-t tests. Second, univariable and multivariable logistic regression models taking into account confounding factors (age, smoking and baseline DAS28)were employed to evaluate the association between autoantibody status and both periods: time to first visit at EAC and to DMARDs initiation. <h3>Results</h3> A total of 463 RA patients were included for analysis, of whom 292 (63.1%) were RF/ACPA double-seropositive (RF+/ACPA+),35 (7.6%)RF-/ACPA+,39 (8.4%) RF+/ACPA- and 92 (19.9%)RF-/ACPA-. Demographic and clinical data are shown in table 1. In the univariate analysis, statiscally significant differences were observed for both periods when patients were stratified by autoantibody serotype, where RF+/ACPA +individuals experienced the longer delay to presentation at EAC compared with RF-/ACPA- (5.0±4.6 vs 3.5±3.4 months;p&lt;0.05). RF+/ACPA +patients experienced also significantly longer symptom duration before DMARD initiation than RF-/ACPA- (7.4±11.2 vs 4.9±5 months;p&lt;0.05). In the univariable analysis, autoabtibody status (doble seropositive and RF-/ACPA +vsRF-/ACPA-) was signficantly asssociated with time to DMARDs initiation. However, after adjusting by confounding factors in the multivariable analysis, the autoantibody status did not remain significantly associated with time to initiate DMARDs (RF+/ACPA-; ß 0.186; p=0.1, RF-/ACPA+; ß 0.112; p=0.3, RF+/ACPA+; ß 0.228; p=0.1) <h3>Conclusions</h3> In our EAC cohort, time to EAC presentation and DMARD initiation following symptom onset in early RA does not differ according to patients' autoantibody status. However, more studies with greater sample size are necessary to confirm these results. <h3>Disclosure of Interest</h3> None declared
AB0154 Notch3 is upregulated in lupus nephritis and its deficiency accelerates lupus progression
Authors: D. Breitkopf, D. Hermert, E. Groene, I. Martin, J. Floege, T. Ostendorf, U. Raffetseder, T. Rauen
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that affects the kidneys in about 50% of patients. Lupus nephritis (LN) is a major risk factor for overall morbidity and mortality in SLE patients. Notch signaling constitutes an evolutionarily conserved pathway that determines major decisions in cell proliferation, survival, and differentiation. <h3>Objectives</h3> To address the role of Notch-3 signalling in the disease development of SLE and particularly LN. <h3>Methods</h3> We measured renal expression of Notch-3 in kidneys of both, LN patients and lupus-prone MRL.<i>lpr</i> mice. Notch-3<sup>-/-</sup> and B6. Fas<sup>lpr/lpr</sup> mice were crossbred to generate a B6. Fas<sup>lpr/lpr</sup> Notch-3<sup>-/-</sup> genotype and we analyzed the spontaneous disease manifestations in 40 week-old mice. Furthermore, we administered antisense oligodeoxynucleotides (ODNs) targeting Notch-3 or scrambled controls in the more aggressive lupus-prone mice strain (MRL. Fas<sup>lpr/lp</sup>) mice starting at week 12 for 3 weeks and analyzed these mice at the age of 16 weeks. <h3>Results</h3> In 20-week old MRL.<i>lpr</i> mice, receptor Notch-3 and its target gene <i>Hes2</i> were significantly up-regulated in kidneys in comparison to 8 and 12 week-old littermates. <i>De novo</i> renal Notch-3 expression in lupus mice and SLE patients was especially pronounced in the glomerular compartment. B6. Fas<sup>lpr/lpr</sup> Notch-3<sup>-/-</sup> mice exhibited an aggravated lupus phenotype with earlier mortality, increased lymph nodes/spleen size, enhanced glomerular collagen IV deposition and increased immune cell infiltration in the kidneys. In line with this, application of anti-sense Notch-3 ODNs in MRL.<i>lpr</i> mice at the time of the transition from clinically inapparent to a manifested disease state (starting at week 12), resulted in accelerated disease progression as evidenced by enhanced lymphadenopathy, splenomegaly and an increase of inflammatory markers <h3>Conclusions</h3> Overall, these results demonstrate that Notch-3 exerts protective effects in the course of SLE, and its deficiency or inhibition accelerates the development of SLE manifestations. <h3>Disclosure of Interest</h3> None declared
New Breast Cancer Screening Technologies in Older Women—Is It Time to Pump the Brakes?
Authors: Ilana B. Richman, Cary P. Gross
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Pre-Clinical Trial to Evaluate the Efficacy of Delayed Administration of Ixazomib in the Prophylaxis of Chronic Graft-Versus-Host Disease
Authors: Teresa Ramos, Alfonso Rodríguez-Gil, Melanie Nufer, María Victoria Barbado, Estefania Garcia Guerrero, Rocio Caracuel-García, Teresa Caballero-Velázquez, José A. Pérez-Simón
Journal: Blood (2018)